BC Innovations | Dec 10, 2019
Product Development

Leon Wang: Let China be China. The next phase in AZ’s China R&D strategy

Leon Wang believes that AstraZeneca has a chance to succeed at R&D in China because its global headquarters has learned to loosen the reins on its satellite premises. A multinational asking locals to carry out...
BioCentury | Jun 19, 2019
Regulation

Why China’s 4 + 7 policy is good news for innovative drug developers

China’s new policy on generic drugs is likely to have knock-on benefits for drug developers aiming to bring innovative compounds to the China market. For multinationals, it will come after some pain, as they’ll see...
BC Week In Review | Feb 9, 2018
Clinical News

Madrigal reports Phase II data of MGL-3196 for HeFH

Madrigal Pharmaceuticals Inc. (NASDAQ:MDGL) reported Phase II data for MGL-3196 (VIA-3196) to treat heterozygous familial hypercholesterolemia (HeFH) that, despite meeting the primary endpoint, suggest the candidate would be unable to compete with marketed drugs in...
BC Extra | Feb 8, 2018
Clinical News

Madrigal falls on Phase II hypercholesterolemia readout

Madrigal Pharmaceuticals Inc. (NASDAQ:MDGL) lost $14.46 (10%) to $131.53 on Thursday after reporting Phase II data for MGL-3196 (VIA-3196) to treat heterozygous familial hypercholesterolemia (HeFH) that, despite meeting the primary endpoint, suggest the candidate would...
BC Extra | Jul 28, 2016
Company News

AZ looks to pipeline, launches to offset patent cliff

In the company's 2Q16 financial presentation on Thursday, AstraZeneca plc (NYSE:AZN; LSE:AZN) CEO Pascal Soriot stressed pipeline progress and growth from new product launches as the company rebuilds from the loss of key products' patent...
BC Week In Review | Jul 25, 2016
Company News

AstraZeneca, Shionogi endocrine/metabolic news

The U.S. District Court for the District of Columbia denied a motion from AstraZeneca seeking a temporary restraining order to prevent FDA from approving generic versions of Crestor rosuvastatin. After the ruling, Mylan N.V. (NASDAQ:MYL,...
BC Extra | Jul 20, 2016
Company News

AZ facing more generic Crestor competition

On Tuesday, a federal judge in the U.S. District Court for the District of Columbia denied a motion from AstraZeneca plc (LSE:AZN; NYSE:AZN) seeking a temporary restraining order to prevent FDA from approving generic versions...
BC Week In Review | May 9, 2016
Clinical News

Rosuvastatin regulatory update

FDA granted final approval to an ANDA from Allergan for a generic version of cholesterol drug Crestor rosuvastatin. The company launched the generic HMG-CoA reductase inhibitor in the U.S. It is approved to treat patients...
BC Innovations | Oct 16, 2014
Distillery Therapeutics

Indication: Musculoskeletal disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Musculoskeletal disease Musculoskeletal disease Fibroblast growth factor receptor 3 (FGFR3; CD333) In vitro and mouse studies suggest statins could help treat achondroplasia, thanatophoric dysplasia type 1...
BC Week In Review | Aug 4, 2014
Clinical News

Alirocumab: Phase III data

Top-line data from the double-blind, international Phase III ODYSSEY COMBO I, COMBO II, OPTIONS I and OPTIONS II trials in patients with hypercholesterolemia and high cardiovascular risk who were not adequately controlled with lipid-lowering therapy...
Items per page:
1 - 10 of 176